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Inflammation and metabolic abnormalities are linked to each other. At present,
pathogenic inflammatory response was recognized as a major player in metabolic
diseases. In humans, intestinal microflora could significantly influence the development
of metabolic diseases including atherosclerosis. Commensal bacteria were shown
to activate inflammatory pathways through altering lipid metabolism in adipocytes,
macrophages, and vascular cells, inducing insulin resistance, and producing
trimethylamine-N-oxide. However, gut microbiota could also play the atheroprotective
role associated with anthocyanin metabolism and administration of probiotics and
their components. Here, we review the mechanisms by which the gut microbiota may
influence atherogenesis.
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Introduction
Intestinal microorganisms are crucially involved in the induction and modulation of mucosal
tolerance (Noverr and Huﬀnagle, 2004; Sanz and De Palma, 2009; Peterson and Cardona,
2010; Tlaskalová-Hogenová et al., 2011; Huang et al., 2013; Ma et al., 2015). Alterations
in mucosal tolerance induced by imbalanced gut microﬂora may lead to acute or chronic
inﬂammation (Sanz and De Palma, 2009; Chow et al., 2010; Lee and Mazmanian, 2010;
Jarchum and Pamer, 2011; Swiatczak and Rescigno, 2012; Magrone and Jirillo, 2013; Chistiakov
et al., 2015). The eﬀects of imbalanced microbiota are not restricted by gastrointestinal
abnormalities but could have systemic impact on immunity (Noverr and Huﬀnagle, 2004;
Huang et al., 2013; Ma et al., 2015). The gut microbiota appears to play role in atherosclerosis,
a chronic vascular inﬂammatory disease, through several mechanisms. In this review, we
consider the role of intestinal microbiota in modulation of atherosclerotic inﬂammatory
response.
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Gut Microbiota and Atherogenesis
Impact of Intestinal Microflora to Metabolic
Abnormalities, a Risk Factor for
Atherosclerosis
Recent data demonstrate that intestinal microorganisms could
inﬂuence lipid metabolism and act as environmental factors
triggering development of metabolic and cardiovascular diseases
(Vrieze et al., 2010; Goldsmith and Sartor, 2014). The lack
of gut microbiota in germ-free apolipoprotein E (ApoE)-
null mice, an experimental model of human atherosclerosis,
was found to induce the development of atherosclerotic
plaques even when animals were fed a standard low-cholesterol
diet. Colonization with normal human microbiota prevented
atherogenesis in germ-free ApoE-null mice fed a standard low-
cholesterol diet but not a diet with high cholesterol content
(Stepankova et al., 2010). Indeed, these observations suggest
on the atheroprotective eﬀects of human colonic commensal
bacteria.
Increased intestinal microbiota-derived lipopolysaccharide
(LPS) load from the colon lumen was shown to be associated
with various metabolic abnormalities including induction
of adipose inﬂammation and insulin resistance (Cani et al.,
2007). Bacterial LPS could be delivered from the gut to the
circulation through chylomicron-associated transport and
via tight junctions in the epithelial lining (Caesar et al.,
2010). LPS is absorbed by enterocytes and transferred to
the Golgi apparatus where chylomicrons synthesized by
enterocytes are stored before secretion (Sabesin and Frase,
1977). Inhibition of chylomicron formation suppressed
intestinal LPS absorption (Ghoshal et al., 2009). High-fat
meal intake increases circulating levels of LPS (Amar et al.,
2008).
Enhanced LPS load across the tight junctions of the gut
epithelium was observed in animal models of human obesity
and associated with the rearrangement of tight junction
proteins, reduced epithelial barrier function, and increased
gut permeability, endotoxemia, and inﬂammation (Brun et al.,
2007; Cani et al., 2008). Administration of antibiotics or
prebiotic oligofructose was shown to improve the integrity of
intestinal epithelium and decrease serum low density lipoproteins
(LDLs) and liver inﬂammation (Cani et al., 2009). Similarly,
treatment of ApoE-null mice with a mixture of eight probiotics
VSL#3 had anti-inﬂammatory eﬀects on the gastrointestinal
tract by decreasing aortic atherosclerosis, steatohepatitis, and
low-grade inﬂammation of intestinal and mesenteric adipose
tissues induced by a high-fat cholesterol intake (Mencarelli
et al., 2012). Therefore, high-fat food leads to unfavorable
changes in gut microbiota that contributes to induction
of metabolic abnormalities in the host organism associated
with primary intestinal epithelial dysfunction and induction
of gastrointestinal inﬂammation that could be reversed by
administration of probiotics and their products (Lee, 2013).
It is essential to note here that ApoE mice naturally develop
atherosclerotic plaque even in the absence of high fat diet
(HFD); however, HFD accelerates this process (Imaizumi,
2011).
Gut Microbiota and Phosphatidylcholine
Metabolism
Recently, a proatherogenic role of the gut microbiota in
the metabolism of phosphatidylcholine was shown (Wang
et al., 2011b). Intestinal microbiota metabolizes choline and
phosphatidylcholine to trimethylamine (TMA), which is further
converted to a proatherogenic compound, trimethylamine-N-
oxide (TMAO; Koeth et al., 2013). Dietary L-carnitine, a
TMA abundant in red meat, is metabolized by intestinal
microbiota to TMAO and accelerates atherosclerosis in ApoE-
null mice through changes in microbial composition and
increased colon production of TMA and TMAO (Ferguson,
2013). The production of TMAO was dependent on variability
of the gut microbiota species. Gut bacteria such as Prevotella
were found to produce more TMAO than Bacteroides. Indeed,
omnivorous people produced more TMAO than did vegetarians.
Increased plasma L-carnitine levels were detected in patients
with cardiovascular abnormalities and were associated with
increased cardiovascular risk (Koeth et al., 2013). Functional
studies showed that TMAO inhibited reverse cholesterol
transport (RCT) and promoted accumulation of cholesterol
in macrophages through increasing cell surface expression of
proatherogenic scavenger receptors (SRs) CD36 and SRA (Wang
et al., 2011b), reducing synthesis of bile acids from cholesterol,
and decreasing expression of bile acid transporters in the liver
(Koeth et al., 2013). Indeed, increased meat consumption could
elevate the dose of L-carnitine and enhance TMAOproduction in
the gut thereby contributing to higher cardiovascular risk. These
ﬁndings create essential prerequisites for possibility to mediate
the atherosclerotic risk through dietary or pharmacological
manipulation of the gut microbiota. However, due to the
complexity of the interactions among host genetics, host diet,
and microbiota and still-limited understanding of speciﬁc
mechanisms of L-carnitine eﬀects on atherogenesis, it is too early
to suggest whether this should be translated into speciﬁc dietary
recommendations.
Reverse Cholesterol Transport
Gut microorganisms were found to be involved in the regulation
of food fat and cholesterol uptake by enterocytes through several
pathways including production of bioactive short-chain fatty
acids such as butyrate and acetate, LPS-mediated activation
of Toll-like receptor 4 (TLR4), and glucagon-like peptide-2-
dependent regulation of epithelial integrity (Musso et al., 2010;
Lee-Rueckert et al., 2013).
Atherosclerosis was shown to be a frequent consequence of
hypercholesterolemia leading to the accumulation of cholesterol
in the vascular wall. RCT is a mechanism that counteracts
the deposition of excess cholesterol in peripheral tissues. RCT-
mediated eﬄux of cholesterol from foam cells accumulated in the
intra-intimal regions of atherosclerotic vessels is believed to be
atheroprotective in early atherosclerotic stages (Tall et al., 2008).
The systemic cholesterol balance and metabolism are regulated
by liver X receptors (LXRs) and nuclear receptors responsive
to stimulation by oxysterols (Zelcer and Tontonoz, 2006). LXR
is critical for cholesterol homeostasis controlling cholesterol
levels by inducing RCT and promoting degradation of lipid
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metabolism-related receptors such as low density lipoprotein
(LDL) receptor, very low density lipoprotein (VLDL) receptor,
and adiponectin receptor 2 (AdipoR2) through transcriptional
induction of Idol (inducible degrader of the LDLR; Zelcer
et al., 2009; Hong et al., 2010). In dividing T cells, LXR
suppresses proliferation through activation of Sterol Regulatory
Element (SRE)-binding protein (SREBP)-mediated cholesterol
synthesis and induction of the oxysterol-metabolizing enzyme
SULT2B1 (sulfotransferase 2B1) associated with inactivation
of the sterol ATP-binding cassette transporter ABCG1 that
uncouples cholesterol transport (Bensinger et al., 2008).
Liver X receptors agonists regulate RCT in macrophages, liver,
and small intestine. In macrophages, LXR stimulates expression
of sterol transporters ABCA1 and ABCG1 responsible for
cholesterol eﬄux (Tall et al., 2008). In the liver, LXR up-regulates
expression of cholesterol-7-α-hydroxylase (CYP7A1) that is
involved in cholesterol catabolism to bile acids (Chiang et al.,
2001). In macrophages, TLR2 and TLR4 suppress stimulation
of LXRs through both myeloid diﬀerentiation primary response
gene (MyD)88-dependent and independent pathways while
apolipoprotein A1, an essential protein component of high
density lipoprotein (HDL) particles and TLR2, TLR4, and CD14
agonist, utilizes MyD88-dependent mechanism to induce RCT
(Smoak et al., 2010). In summary, LXRs play a remarkable
role on crossroads of metabolic, cell cycle, and immune
signaling.
Gut Microbiota and Anthocyanin Metabolism
Recent ﬁndings showed that the intestinal microbiota has a
new mechanism associated with the metabolism of anthocyanin
that could be useful for atheroprotection. Protocatechuic acid
(PCA), a metabolite of cyanidin-3-O-β-glucoside (α-G) was
shown to have a profound anti-atherogenic eﬀect (Wang
et al., 2010). PCA was found to promote cholesterol eﬄux
from macrophages through activation of expression of ABCA1
and ABCG1 by down-regulating microRNA (miR)-10b that
target both cholesterol transporters (Hazen and Smith, 2012;
Wang et al., 2012a). PCA is directly produced by gut
microbiota from Cy-3-G. The main fruit sources of Cy-3-
G and other cyanidins are blackberries and bilberries. Other
dietary sources include chokeberries, boysenberries, elderberries,
purple vegetables (such as carrots and yams), black raspberries,
and Hibiscus sabdariﬀa extract. In ApoE-null mice, both PCA
and Cy-3-G were reported to attenuate atherosclerosis (Wang
et al., 2011a). Cy-3-G was able to improve serum cholesterol
levels in ApoE-null mice and increase formation of bile
acids through activation of liver expression of CYP7A1 via
direct binding to LXRα (Wang et al., 2012b). In addition,
Cy-3-G could eﬃciently block atherosclerotic progression
in ApoE-null mice fed on a high-fat diet by improving
hypercholesterolemia-induced endothelial dysfunction through
reducing circulating levels of cholesterol and 7-ketocholesterol
and restoring production of nitric oxide (NO) by vascular
endothelial cells (Zhang et al., 2013). However, compared to Cy-
3-G, PCA showed the anti-atherogenic eﬀect at physiologically
reachable concentrations that makes it to be potentially
signiﬁcant for therapeutic use.
In intimal macrophages and vascular smooth muscle cells
(VSMCs), TLR2/4/MyD88 pathway is involved in support
of the proatherogenic intracellular cholesterol accumulation
stimulated by bacterial LPS derived from E. coli and oxLDL
(Higashimori et al., 2011). In foam cells, LXRs and TLR2/4
were shown to regulate intracellular cholesterol transport by
reciprocal inhibition of each other (Cao et al., 2007; Chen
et al., 2008). The proinﬂammatory anthocyanin pigment Cy-3-
G presented in the human diet was shown to inhibit TLR4-
mediated proinﬂammatory signaling in macrophages by up-
regulation of the LXRα/ABCG1 axis that activates RCT resulted
in subsequent disrupting lipid rafts by depleting cholesterol
and limiting translocation of TLR4 to lipid rafts (Fu et al.,
2014).
Atheroprotective Role of Probiotic
Microorganisms
Consumption of a probiotic strain DSM 9843 of Lactobacillus
plantarum by men with carotid atherosclerosis showed some
beneﬁcial eﬀects for the host associated with increase of the
bacterial diversity in the gut and with changes in colon levels of
certain short-chain fatty acids (Karlsson et al., 2010). Similarly,
Naruszewicz et al. (2002) demonstrated that another strain 299v
of L. plantarum was able to reduce several cardiovascular disease
risk factors in smokers including positive metabolic changes,
decrease in levels of proinﬂammatory cytokine IL-6, and reduced
adhesion of monocytes to endothelial cells. On the other hand,
administration of L. delbrüeckii in ApoE-null mice fed on
a hypercholesterolemic diet had only modest atheroprotective
eﬀect (Portugal et al., 2006). Limited anti-atherogenic eﬀects
of human intestinal microbiota in case of uptake of a high-fat
diet may be explained by positive association of some human
commensals such as Firmicutes and Bacteroidetes with obesity
due to increased capability of these microbes to metabolize ﬁber
into short chain fatty acids that could be converted to fat in high
lipid load (Turnbaugh et al., 2006). In mice fed a high-fat diet,
consumption of probiotic bacteria L. rhamnosus GG and L. sakei
NR28 had beneﬁcial anti-obesity eﬀects through reduction in
the small intestine frequency of obesity-associated commensals
Firmicutes and Bacteroidetes, decrease of epididymal fat mass
and down-regulation of liver lipid-synthesizing enzymes (Ji et al.,
2012).
Impact of Gut Microbiota to Metabolic
Inflammation and Atherosclerosis
Accumulated data have revealed a close relationship between
inﬂammatory and metabolic pathways. Indeed, inﬂammation
was recognized to signiﬁcantly contribute to the pathogenesis
of obesity, insulin resistance, and atherosclerosis. Traditionally,
colonic bacteria were considered as agents activating
inﬂammatory mechanisms. This is supported by multiple
data showing the link between the gut microbiota, inﬂammation,
and autoimmunity.
Colonic microbiota could stimulate inﬁltration of
macrophages in the adipose tissue by providing inﬂammatory
stimuli such as LPS and enhancing energy intake from the
food that leads to adipocyte hypertrophy (Bäckhed et al.,
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FIGURE 1 | Mechanisms by which gut microbiota could influence
the development of atherosclerosis. Intestinal microbiota may have
both pro- and anti-atherogenic effects. Probiotics have the
atheroprotective activity through the release of bioactive short-chain fatty
acids that in turn inhibit fat synthesis in adipocytes and enterocytes
and suppress cholesterol biosynthesis and formation of proatherogenic
low density lipoproteins (LDL) in the liver. In addition, probiotics and
their products could down-regulate inflammation thereby indirectly
decreasing the atherosclerosis progression. In addition, anthocyanins
presented in some barriers, fruits, and green tea could be metabolized
by colon microflora to protocatechuic acid (PCA), a bioactive molecule
that could increase expression of ATP-binding cassette transporters
ABCA and ABCG and in macrophages and therefore stimulate
cholesterol efflux and inhibit macrophage transformation to foam cells,
a hallmark of early atherosclerosis. PCA could stimulate cholesterol
catabolism and bile acid synthesis via up-regulation of liver cholesterol
7 α-hydroxylase CYP7A1, an enzyme, which oxidizes cholesterol.
However, gut microbiota could also exhibit proatherogenic effects.
Commensal bacteria such as Firmicutes sp. and Bacteroidetes sp.
release lipopolysaccharides (LPS) that could be recognized by Toll-like
receptor (TLR)4 and down-regulate expression of transcription factor liver
X receptor (LXR)-á (suppressor of cholesterol uptake) while expression
of proatherogenic LDL receptor, very low density lipoprotein (VLDL)
receptor, and adiponectin receptor 2 (AdipoR2) become up-regulated in
macrophages. Indeed, this leads to elevated lipid uptake by
macrophages promoting their transformation to foam cells. Furthermore,
intestinal-derived LPS were shown to decrease the production of
glucagon-like peptide 2 (GLP2) intestinal neuroendocrine L-cells, which
results in weakened colon epithelial integrity, increased efflux of colon
biomaterial outside the intestine, and enhanced inflammation. Finally,
some species of intestinal microbiota were found to show increased
capacity to metabolize choline and L-carnitine, which are enriched in
red meat, to trimethylamine (TMA) and trimethylamine-N-oxide (TMAO).
Elevated levels of TMAO are associated with increased cardiovascular
risk. TMAO is able to activate expression of LDL scavenger receptors
SRA and CD36 in macrophages thereby stimulating LDL uptake and
formation of foam cells. In hepatocytes, TMAO suppress both bile acid
synthesis from cholesterol and expression of bile acid transporters.
Abbreviations: Cy-3-G, cyanidin-3-O-â-glucoside; IL-6, interleukin 6;
TNF-á, tumor necrosis factor á; SRA, scavenger receptor A.
2004). Free fatty acids and bacterial LPS act synergistically in
stimulation of adipose inﬂammation. Therefore, it is diﬃcult
to determine speciﬁc contribution of the gut microbiota to
metabolic inﬂammation.
Toll-like receptor 4 seems to play a role of the molecular
link between metabolism, nutrition, and inﬂammation.
Proinﬂammatory macrophages inﬁltrating the adipose tissue
are activated by fatty acids through TLR2 and TLR4 stimulation
(Nguyen et al., 2007). Adipocyte-derived saturated fatty acids
also induce nuclear factor (NF)-κB-mediated expression of
tumor necrosis factor (TNF)-α and other proinﬂammatory
genes via TLR4-dependent mechanism (Suganami et al., 2007).
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A paracrine loop involving fatty acids and TNF-α mediates
reciprocal proinﬂammatory changes in adipocytes and
inﬁltrating macrophages during the adipose-associated
inﬂammation (Suganami et al., 2005).
In fact, LPS represents an endotoxin whose production by
gut microbes could lead to chronic low-grade inﬂammation
and contribute to progression of obesity, insulin resistance,
metabolic syndrome, and diabetes, e.g., well recognized
atherogenic risk factors (Cani et al., 2007; Jialal and Rajamani,
2014). Increased intestinal permeability results in elevated
endotoxin levels in the circulation that could aﬀect lipid
metabolism and induce low-grade inﬂammatory response
associated with higher cardiovascular risk (Teixeira et al., 2012).
Unlike high-dose LPS, low-dose LPS does not initiate marked
activation of NF-κB, mitogen-activated protein kinases (MAPK),
phosphatidylinositol-3-kinases (PI3K), or anti-inﬂammatory
mediators. Instead, low-dose LPS induce hepatocyte nuclear
factor 1 homeobox B (HNF1B) through Toll-interacting protein-
mediated generation of mitochondrial reactive oxygen species,
allowing mild induction of proinﬂammatory mediators. Low-
dose LPS also down-regulates PI3K and related negative
regulators of inﬂammatory genes (Maitra et al., 2012). In
addition to the modest activation of proinﬂammatory genes,
low-dose endotoxin was found to reduce expression of proteins
involved in reverse cholesterol transport such as ABCA1/ABCG1
and SR-B1 in murine macrophages (Maitra and Li, 2013).
Even superlow doses of LPS could show deleterious eﬀects
in primary cultures of mouse macrophages by inducing
mitochondrial ﬁssion and cell necroptosis through ubiquitination
and degradation of mitofusin 1 (Mfn1; a molecule needed
for proper mitochondrial fusion) and dephosphorylation and
activation of Drp1 (a molecule responsible for mitochondrial
ﬁssion and cell necroptosis). This process is mediated
by interleukin 1 receptor-associated kinase (IRAK-1) and
receptor-interacting protein 3 kinase (RIP3), e.g., molecules
critical for the assembly of the necrosome complex (Baker
et al., 2014). Indeed, LPS at low dose and superlow dose
exploit diﬀerent pathogenic mechanisms in macrophage
cytotoxicity.
In addition to LPS, the microbiota produces many
other proinﬂammatory molecules including ﬂagellin,
peptidoglycan, etc. recognized by TLRs and other PRRs.
For example, peptidoglycan derived from the gut microbiota
systemically drives the innate immune system stimulating
killing two major pathogens Streptococcus pneumoniae
and Staphylococcus aureus by bone marrow neutrophils
(Clarke et al., 2010). Peptidoglycan-mediated mechanism
of neutrophil activation requires recognition by the PRRs
such as the nucleotide-binding, oligomerization domain-
containing protein-1 (Nod1) and TLR4 (Chamaillard et al.,
2003).
In human atherosclerotic lesions, several TLRs including
TLR2 and TLR4 are expressed in proinﬂammatory macrophages
and vascular cells (Monaco et al., 2009). Activation of TLR2
and TLR4 is mediated by MyD88 that in turn is responsible
for providing proatherogenic and proinﬂammatory signals
(Fitzgerald et al., 2001). The atherogenic role of these signaling
molecules is supported by observations in ApoE-null mice
deﬁcient for TLR2, TLR4, or MyD88 that have attenuated
atherosclerosis (Michelsen et al., 2004). In MyD88-null mice,
cholesterol metabolism and uptake of oxidized LDL (oxLDL)
were not altered but macrophage adhesion to the vascular
endothelium was impaired due to reduced expression of
chemokines (Björkbacka et al., 2004).
Bacterial LPS were shown to activate proinﬂammatory
production of matrix metalloproteinase (MMP)-9 through
TLR2/4 activation in macrophages, VSMCs, and endothelial
cells that could lead to the atherosclerosis-associated vascular
remodeling and plaque destabilization (Li et al., 2012; Paolillo
et al., 2012). LXRα could eﬃciently block up-regulation of
MMP-9 in LPS-stimulated macrophages by repressing TLR2/4-
dependent stimulation (Castrillo et al., 2003). Indeed, a crosstalk
between proatherogenic TLR2/4 and atheroprotective LXR
signaling in vascular cells and macrophages could contribute
to the development of atherosclerotic disease and mediate
atherogenic or anti-atherogenic eﬀects of bacterial components
such as LPS and bacterial metabolites such as Cy-3-G.
Concluding Remarks
The mechanisms responsible for the induction of immune
tolerance in atherogenesis have been discussed in a number
of recent reviews (Ketelhuth and Hansson, 2011; Perrins and
Bobryshev, 2011; Broder et al., 2013; Van Brussel et al., 2014).
Mechanisms by which gut microbiota could inﬂuence the
development of atherosclerosis are summarized in Figure 1.
Albeit the information about the impact of the intestinal
microbiota to atherogenesis is still limited and ‘fragmented,’
accumulating knowledge unambiguously indicates that the
intestinal microbiota inﬂuences host immunity and contributes
to atherosclerosis.
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